"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
| Descriptor ID |
D009465
|
| MeSH Number(s) |
D27.505.696.663.700
|
| Concept/Terms |
Neuromuscular Effect- Neuromuscular Effect
- Effect, Neuromuscular
- Neuromuscular Effects
- Effects, Neuromuscular
|
Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".
This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 5 | 5 | 10 |
| 2018 | 8 | 3 | 11 |
| 2019 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.
-
A Randomized, Single-Blind, Crossover Study Evaluating the Impact of OnabotulinumtoxinA Treatment on Mood and Appearance During the COVID-19 Pandemic. Aesthet Surg J. 2021 08 13; 41(9):NP1199-NP1205.
-
Feasibility of sit training for patients with severe COVID-19 pneumonia during deep sedation: A case report. Medicine (Baltimore). 2021 Jun 04; 100(22):e26240.
-
The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany. Toxins (Basel). 2021 01 29; 13(2).
-
Discontinuation of botulinum neurotoxin type-A treatment during COVID-19 pandemic: an Italian survey in post stroke and traumatic brain injury patients living with spasticity. Eur J Phys Rehabil Med. 2021 Jun; 57(3):424-433.
-
Impact of COVID-19 on neurological patients attending a botulinum toxin service. Neurol Sci. 2021 02; 42(2):433-435.
-
Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway. J Headache Pain. 2020 Oct 29; 21(1):128.
-
Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. J Headache Pain. 2020 Sep 24; 21(1):115.
-
A risk-stratified approach toward safely resuming OnabotulinumtoxinA injections based on dosing and ambulatory status in pediatric patients with cerebral palsy during the Coronavirus pandemic of 2019 (COVID-19). J Pediatr Rehabil Med. 2020; 13(3):273-279.
-
Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis. Toxins (Basel). 2019 07 01; 11(7).
-
CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA. J Headache Pain. 2019 Apr 23; 20(1):39.